The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 35, 2014, Pages

  Semenas, Julius ^a   Hedblom, Andreas ^a   Miftakhova, Regina R ^a   Sarwar, Martuza ^a   Larsson, Rikard ^b   Shcherbina, Liliya ^a   Johansson, Martin E ^b   Härkönene, Pirkko ^c   Sterner, Olov ^b   Persson, Jenny L ^a  

^a Clinical Research Center   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Cancer metastasis; Drug discovery; Kinase inhibitor; Targeted therapy

Indexed keywords

CANCER METASTASIS; DRUG DISCOVERY; KINASE INHIBITOR; TARGETED THERAPY;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; DIKETOPIPERAZINES; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; INDOLES; ISOQUINOLINES; MALE; MICE; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TETRAHYDROISOQUINOLINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907227933     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1405801111     Document Type: Article

References (40)

1. Sharma SV, Haber DA, Settleman J (2010) Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 10(4):241-253.
2. Hijikata-Okunomiya A, Okamoto S, Wanaka K (1990) Effect of a synthetic thrombin-inhibitor MD805 on the reaction between thrombin and plasma antithrombin-III. Thromb Res 59(6):967-977.
3. Ramnauth J, et al. (2012) 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors: Lead optimization studies resulting in the identification of N-(1-(2-(methylamino)ethyl)-1,2,3,4- tetrahydroquinolin-6-yl)thiophene-2-carboximidamide as a preclinical development candidate. J Med Chem 55(6):2882-2893.
4. Oku N, Matsunaga S, van Soest RW, Fusetani N (2003) Renieramycin J, a highly cytotoxic tetrahydroisoquinoline alkaloid, from a marine sponge Neopetrosia sp. J Nat Prod 66(8):1136-1139.
5. Ferris JP, Guillemin JC (1990) Photochemical cycloaddition reactions of cyanoacetylene and dicyanoacetylene. J Org Chem 55(21):5601-5606.
6. Hawkins JM, et al. (1990) Organic chemistry of C60 (Buckminsterfullerene) : Chromatography and osmylation. J Org Chem 55(26):6250-6252.
7. Brown JR, Auger KR (2011) Phylogenomics of phosphoinositide lipid kinases: Perspectives on the evolution of second messenger signaling and drug discovery. BMC Evol Biol 11:4.
8. Engelman JA (2009) Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer 9(8):550-562.
9. Loijens JC, Boronenkov IV, Parker GJ, Anderson RA (1996) The phosphatidylinositol 4-phosphate 5-kinase family. Adv Enzyme Regul 36:115-140.
10. Emerling BM, et al. (2013) Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors. Cell 155(4):844-857.
11. Ishihara H, et al. (1996) Cloning of cDNAs encoding two isoforms of 68-kDa type I phosphatidylinositol-4-phosphate 5-kinase. J Biol Chem 271(39):23611-23614.
12. Ishihara H, et al. (1998) Type I phosphatidylinositol-4-phosphate 5-kinases. Cloning of the third isoform and deletion/substitution analysis of members of this novel lipid kinase family. J Biol Chem 273(15):8741-8748.
13. Loijens JC, Anderson RA (1996) Type I phosphatidylinositol-4-phosphate 5-kinases are distinct members of this novel lipid kinase family. J Biol Chem 271(51):32937-32943.
14. Xie Y, Zhu L, Zhao G (2000) Assignment of type I phosphatidylinositol-4- phosphate 5-kinase (PIP5K1A) to human chromosome bands 1q22-> q24 by in situ hybridization. Cytogenet Cell Genet 88(3-4):197-199.
15. Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441(7092):424-430.
16. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4(12):988- 1004.
17. Saito K, et al. (2003) BTK regulates PtdIns-4,5-P2 synthesis: Importance for calcium signaling and PI3K activity. Immunity 19(5):669-678.
18. Somanath PR, Razorenova OV, Chen J, Byzova TV (2006) Akt1 in endothelial cell and angiogenesis. Cell Cycle 5(5):512-518.
19. Chen YL, Law PY, Loh HH (2005) Inhibition of PI3K/Akt signaling: An emerging paradigm for targeted cancer therapy. Curr Med Chem Anticancer Agents 5(6):575-589.
20. Wang Y, Kreisberg JI, Ghosh PM (2007) Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets 7(6):591-604.
21. Culig Z, et al. (1999) Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81(2):242-251.
22. Nguyen TV, Yao M, Pike CJ (2007) Flutamide and cyproterone acetate exert agonist effects: Induction of androgen receptor-dependent neuroprotection. Endocrinology 148(6):2936-2943.
23. Huggins C, Hodges CV (2002) Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 167(2 Pt 2):948-951, discussion 952.
24. Semenas J, Dizeyi N, Persson JL (2013) Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer. Drug Des Devel Ther 7:875-881.
25. Huggins C (1963) The hormone-dependent cancers. JAMA 186(5):481-483.
26. Koivisto P, et al. (1997) Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57(2):314-319.
27. StanbroughM, et al. (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66(5):2815-2825.
28. Montgomery RB, et al. (2008)Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 68(11):4447-4454.
29. Sasaki J, et al. (2005) Regulation of anaphylactic responses by phosphatidylinositol phosphate kinase type I alpha. J Exp Med 201(6):859-870.
30. Hasegawa H, et al. (2012) Phosphatidylinositol 4-phosphate 5-kinase is indispensable for mouse spermatogenesis. Biol Reprod 86(5):136, 1-12.
31. Yamaguchi H, et al. (2010) Phosphatidylinositol 4,5-bisphosphate and PIP5-kinase Ialpha are required for invadopodia formation in human breast cancer cells. Cancer Sci 101(7):1632-1638.
32. Larsson R, Blanco N, Johansson M, Sterner O (2012) Synthesis of C-1 indol-3-yl substituted tetrahydroisoquinoline derivatives via a Pictet-Spengler approach. Tetrahedron Lett 53(37):4966-4970.
33. Goldstein DM, Gray NS, Zarrinkar PP (2008) High-throughput kinase profiling as a platform for drug discovery. Nat Rev Drug Discov 7(5):391-397.
34. Merkle D, Hoffmann R (2011) Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: Cross-talk with the androgen receptor. Cell Signal 23(3):507-515.
35. Taylor BS, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1):11-22.
36. Dienstmann R, Rodon J, Markman B, Tabernero J (2011) Recent developments in anticancer agents targeting PI3K, Akt and mTORC1/2. Recent Patents Anticancer Drug Discov 6(2):210-236.
37. Deep G, Oberlies NH, Kroll DJ, Agarwal R (2008) Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway. Oncogene 27(28):3986-3998.
38. Carver BS, et al. (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19(5):575-586.
39. Mulholland DJ, et al. (2011) Cell autonomous role of PTEN in regulating castrationresistant prostate cancer growth. Cancer Cell 19(6):792-804.
40. Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP (2006) Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci USA 103(43):15969-15974.